Federation des caisses Desjardins du Quebec’s Nektar Therapeutics NKTR Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18	Closed	-$4.76K	–	2572
2021 Q3	$4.76K	Hold	18	–	–	﹤0.01%	2251
2021 Q2	$4.55K	Hold	18	–	–	﹤0.01%	2273
2021 Q1	$5.3K	Hold	18	–	–	﹤0.01%	2184
2020 Q4	$4.5K	Hold	18	–	–	﹤0.01%	2102
2020 Q3	$4.4K	Sell	18 -20	-53%	-$6.29K	﹤0.01%	1882
2020 Q2	$13.1K	Hold	38	–	–	﹤0.01%	1561
2020 Q1	$10.1K	Sell	38 -32	-46%	-$9.9K	﹤0.01%	1668
2019 Q4	$22.8K	Hold	70	–	–	﹤0.01%	1703
2019 Q3	$19.2K	Hold	70	–	–	﹤0.01%	1682
2019 Q2	$37.5K	Buy	70 +20	+40%	+$10K	﹤0.01%	1547
2019 Q1	$25.4K	Buy	50 +32	+178%	+$19K	﹤0.01%	1463
2018 Q4	$8.71K	Sell	18 -3	-14%	-$1.81K	﹤0.01%	1654
2018 Q3	$19.1K	Buy	21 +3	+17%	+$2.56K	﹤0.01%	1568
2018 Q2	$12.9K	Sell	18 -3	-14%	-$3.46K	﹤0.01%	1684
2018 Q1	$33.5K	Buy	+21	New	+$27.1K	﹤0.01%	1444

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's NKTR Position: Q4 2021 in Review

Federation des caisses Desjardins du Quebec sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 18 shares — an estimated $4.76K sold.

Federation des caisses Desjardins du Quebec first reported a position in NKTR in Q1 2018 and held it in 15 quarters. The position peaked at $37.5K in Q2 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

Federation des caisses Desjardins du Quebec reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 18 Nektar Therapeutics shares in Q4 2021, an estimated $4.76K.
Federation des caisses Desjardins du Quebec first reported a position in Nektar Therapeutics in Q1 2018 and held it in 15 quarters.
Federation des caisses Desjardins du Quebec's Nektar Therapeutics position peaked at $37.5K in Q2 2019.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2021, filed 30 Aug 2024.